MedPath

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

🇸🇬Singapore
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 4:1

Drug Approvals

18

HSA:18

Drug Approvals

EYBELIS-S OPHTHALMIC SOLUTION 0.002%w/v

Approval Date
Feb 19, 2024
HSA

LATANO SANTEN OPHTHALMIC SOLUTION, 0.005%w/v

Approval Date
Aug 31, 2023
HSA

ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V

Approval Date
Jul 4, 2023
HSA

RHOPRESSA OPHTHALMIC SOLUTION, 0.02% w/v

Approval Date
Jul 4, 2023
HSA

DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML

Approval Date
Sep 7, 2022
HSA

EYBELIS OPHTHALMIC SOLUTION 0.002%

Approval Date
Apr 7, 2021
HSA

COSOPT-S OPHTHALMIC SOLUTION

Approval Date
Feb 26, 2018
HSA

IKERVIS EYE DROPS, EMULSION 1MG/ML

Approval Date
Apr 20, 2017
HSA

TAPCOM-S OPHTHALMIC SOLUTION

Approval Date
Aug 2, 2016
HSA

CRAVIT OPHTHALMIC SOLUTION 1.5% w/v

Approval Date
Jul 18, 2016
HSA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 4
1 (100.0%)

Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl

Phase 4
Conditions
Normal Tension Glaucoma
Primary Open-angle Glaucoma
Glaucoma, Suspect
Ocular Hypertension
Interventions
Drug: Eybelis ophthalmic solution 0.002%
First Posted Date
2022-03-15
Last Posted Date
2022-03-15
Lead Sponsor
Santen Pharmaceutical Asia Pte. Ltd.
Target Recruit Count
150
Registration Number
NCT05279716
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Kangbuk Samsung Hospital, Seoul, Korea, Republic of

and more 5 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.